Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rodenhuis

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|April 1, 1995
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approachE van der Wall, W J Nooijen, J W Baars, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancerM T Huizing, L J van Warmerdam, H Rosing, et al.
Lancet (London, England)|August 26, 1998
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvementS Rodenhuis, D J Richel, E van der Wall, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyJ Verweij, A van Oosterom, J-Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-upJ G Schrama, I F Faneyte, J H Schornagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancerG C de Gast, F A Vyth-Dreese, W Nooijen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedureL J van Warmerdam, G J Creemers, S Rodenhuis, et al.
Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.
Anticancer Research|September 1, 1996
Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumoursJ W Baars, M J Holtkamp, W J Nooyen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 17, 2016
PET/CT with <sup>18</sup>F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal diseaseS C Teixeira, B B Koolen, P H M Elkhuizen, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|April 1, 1995
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approachE van der Wall, W J Nooijen, J W Baars, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancerM T Huizing, L J van Warmerdam, H Rosing, et al.
Lancet (London, England)|August 26, 1998
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvementS Rodenhuis, D J Richel, E van der Wall, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyJ Verweij, A van Oosterom, J-Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-upJ G Schrama, I F Faneyte, J H Schornagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancerG C de Gast, F A Vyth-Dreese, W Nooijen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedureL J van Warmerdam, G J Creemers, S Rodenhuis, et al.
Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.
Anticancer Research|September 1, 1996
Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumoursJ W Baars, M J Holtkamp, W J Nooyen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 17, 2016
PET/CT with <sup>18</sup>F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal diseaseS C Teixeira, B B Koolen, P H M Elkhuizen, et al.
Pageof 15